Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Strategic Partnership

10 Jun 2013 07:00

RNS Number : 6083G
Ideagen PLC
10 June 2013
 



 

Ideagen plc

("Ideagen" or the "Company")

 

Strategic Partnership with a Leading Global Medical Device Manufacturer

 

Ideagen PLC (AIM: IDEA), a leading supplier of Compliance based Information Management solutions is pleased to announce that it has signed a strategic partnership with a leading global manufacturer of medical devices to supply the company's order communications software, dartOCM, into the UK NHS.

 

DartOCM is an application platform which provides context related intelligent information management of pathology services for both hospitals and GP clinicians. The solution enables the ordering of appropriate tests while delivering "paperless" results back to the clinician with real time notifications and alerts in a centralised patient record.

 

The UK NHS is currently undergoing a consolidation of its pathology services in line with the Carter report (2008), which stated that reform was key and could deliver £500m savings annually whilst improving service levels. "Consolidation of pathology services into reconfigured networks will improve services for patients by enhancing value for money and releasing resources for investment to improve service quality and patient safety". To date 2 regional networks have been announced with additional regions expected to be announced over the next year.

 

The partnership has resulted in an immediate £150k contract to supply the dartOCM system to an Acute Trust in the Midlands, which will be used as a 'lighthouse' pilot to demonstrate the compelling value proposition of the solution in terms of both operational and financial benefits. It is expected that, if successful, the planned regional roll out will generate a significant, multi-year contract for Ideagen supporting 10,000 users across 700 sites, and provide a strong reference to accelerate further roll-outs in to new networks across the country.

 

David Hornsby Chief Executive said: ''I am delighted that we have been selected to support this important programme for the NHS. There is a significant market opportunity to provide dartOCM to streamline the test and results process in supporting the consolidation of pathology services within the NHS. To be selected as the preferred technology platform by a global leader in the field of medical diagnostic equipment is a testament to our prominent position in this area''

Enquiries:

Ideagen Plc

Tel: 01629 761590

David Hornsby, Chief Executive

Graeme Spenceley, Finance Director

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Matt Goode/ Charlotte Stranner (Corporate Finance)

Stephen Norcross (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780

Helen Westaway

Helen.westaway@walbrookpr.com

Paul Cornelius

Paul.cornelius@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKODQPBKDBAK
Date   Source Headline
24th Sep 201810:42 amRNSHolding(s) in Company
17th Sep 20184:42 pmRNSExercise of Options and Total Voting Rights
17th Sep 20184:33 pmRNSHolding(s) in Company
13th Sep 20185:00 pmRNSClosing of conditional Placing to raise £20m
13th Sep 201811:30 amRNSProposed Placing to raise £20 million
5th Sep 20187:00 amRNSAcquisition of InspectionXpert Inc
3rd Sep 20182:36 pmRNSExercise of Options and Total Voting Rights
15th Aug 201812:23 pmRNSHolding(s) in Company
13th Aug 20183:18 pmRNSHolding(s) in Company
13th Aug 20183:05 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Aug 20181:08 pmRNSHolding(s) in Company
23rd Jul 20183:27 pmRNSIssue of Equity
17th Jul 20187:00 amRNSUnaudited Preliminary Results
18th Jun 20183:38 pmRNSExercise of Options and Total Voting Rights
11th Jun 20185:00 pmRNSIssue of Equity and Total Voting Rights
22nd May 20183:59 pmRNSIssue of Shares under Share Incentive Plan and TVR
15th May 20183:10 pmRNSExercise of Options and Total Voting Rights
9th May 20187:00 amRNSExercise of Options and Total Voting Rights
8th May 20187:00 amRNSPre-Close Trading Update and Board Changes
18th Apr 201810:12 amRNSIssue of Equity
12th Apr 201810:35 amRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
6th Apr 20187:00 amRNSAcquisition of Medforce Technologies Inc
26th Mar 201812:38 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSIssue of Shares under Share Incentive Plan and TVR
6th Mar 20183:58 pmRNSExercise of Options and Total Voting Rights
14th Feb 20187:00 amRNSIssue of Equity
23rd Jan 20187:00 amRNSInterim Results
11th Jan 20187:00 amRNSIssue of Equity
13th Dec 201710:18 amRNSDirector Dealing
11th Dec 20172:26 pmRNSIssue of Equity
4th Dec 201712:37 pmRNSExercise of Options and Total Voting Rights
23rd Nov 20177:00 amRNSContract Win
10th Nov 20173:07 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Nov 20171:26 pmRNSExercise of Options and Total Voting Rights
7th Nov 20177:00 amRNSTrading Update
1st Nov 20175:18 pmRNSPDMR / PCA Dealing
30th Oct 20171:33 pmRNSResult of AGM
25th Oct 20177:00 amRNSExercise of Options and Total Voting Rights
23rd Oct 201710:55 amRNSExercise of Options and Total Voting Rights
16th Oct 20173:30 pmRNSExercise of Options and Total Voting Rights
9th Oct 20174:09 pmRNSIssue of shares under the Share Incentive Plan
6th Oct 20173:13 pmRNSNotice of AGM
27th Sep 20174:28 pmRNSExercise of Options and Total Voting Rights
20th Sep 201710:08 amRNSHolding(s) in Company
4th Sep 20177:00 amRNSBoard Appointment
1st Sep 20173:06 pmRNSIssue of shares under a Share Incentive Plan
11th Aug 20173:00 pmRNSHolding(s) in Company
11th Aug 20178:00 amRNSHolding(s) in Company
10th Aug 20171:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.